Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of AVIR is 8.6 and suggests 41% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell